Charles River Laboratories Implements BioTrove High-Throughput SNP Genotyping System
April 18 2006 - 8:25AM
Business Wire
Charles River Laboratories International, Inc. (NYSE: CRL), a
premier global provider of solutions that advance the drug
discovery and development process, announces that it has adopted
the OpenArray(TM) SNP Genotyping System from BioTrove. The BioTrove
OpenArray platform will be used in Charles River's rigorous genetic
quality control process. Using this high-throughput genotyping
platform, Charles River will be able to rapidly analyze thousands
of samples for SNP analysis per month, ensuring researchers the
congenicity of their inbred and first generation hybrid strains
used in biomedical studies. The OpenArray platform produces
thousands of parallel PCR reactions for SNP analysis utilizing
standard homogeneous assays. Now, researchers may rapidly test
validated SNPs of interest against hundreds or even thousands of
DNA samples. "We have been impressed with the BioTrove OpenArray
platform in many ways. The BioTrove's flexibility, strong
genotyping performance, and throughput capabilities make quality
control testing of multiple samples possible using many more
genetic markers. In addition, the OpenArrays can be formatted in
any configuration to provide for future applications," said Dr.
Bruce Elder, Director of Corporate Rodent Genetics at Charles River
Laboratories. "We are pleased to be working with a market leader
like Charles River. Their implementation of high-throughput sample
genotyping will enable them to quickly respond to their customers'
needs today with the ability to expand as their genetic testing
services continue to grow," said Alan Carter, Chief of Commercial
Operations. About Charles River Laboratories Charles River
Laboratories, based in Wilmington, Massachusetts, U.S., is a global
provider of solutions that advance the drug discovery and
development process. Our leading-edge products and services are
designed to enable our clients to bring drugs to market faster and
more efficiently. Backed by our rigorous, best-in-class procedures
and our proven data collection, analysis and reporting
capabilities, our products and services are organized into three
categories spanning every step of the drug development pipeline:
Research Models and Services, Preclinical Services, and Clinical
Services. Charles River's customer base includes all of the major
pharmaceutical companies and many biotechnology companies,
government agencies and leading hospitals and academic
institutions. Charles River's 8,400 employees serve clients in more
than 50 countries. For more information on Charles River, visit our
website at www.criver.com. About BioTrove BioTrove offers two
innovative platform technologies that dramatically increase the
throughput of SNP genotyping and pharmaceutical screening. The
OpenArray(TM) platform enables genomics researchers to generate up
to hundreds of thousands of data points per day. The flexible
format of the OpenArray(TM) plate allows researchers to adjust to
their changing needs in sample and assay numbers. Additionally, the
nanoliter scale of this flexible system makes high-throughput
genotyping economical. RapidFire(TM) Lead Discovery enables drug
developers to analyze samples using ultra high-throughput mass
spectrometry in less than 8 seconds per sample. This technology
enables difficult targets (lipids, fatty acids, phospholipids,
steroids, and prostaglandins) to be tested using a high-throughput,
native detection method.
Charles River Laboratories (NYSE:CRL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Charles River Laboratories (NYSE:CRL)
Historical Stock Chart
From Sep 2023 to Sep 2024